A Phase 4 interventional study of dupilumab and Matching placebo in Asthma, sponsored by Regeneron Pharmaceuticals. Completed at 30 sites in 5 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-04-18.
Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 25th largest by enrollment, is one of 4 that started in 2020, is one of 14 in phase 4, and was the 14th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2020.
This study's enrollment of 40 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 8 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.
The secondary objectives of the study are:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A loading dose at the start of the treatment followed by once every two weeks (Q2W).
Drug: dupilumab
Matching dupilumab
Drug: Matching placebo
Pre-filled syringe administered by subcutaneous (SC) injections
Also known as: Dupixent®, SAR231893
Pre-filled syringe administered by subcutaneous (SC)
Change From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test)
CWRET (Constant Work Rate Exercise Test) will be performed on an electromagnetically-braked cycle ergometer in an exercise physiology laboratory overseen by a trained pulmonologist or medical doctor designee.
Time frame: Up to week 12
Change From Baseline to Week 12 in Average Number of Steps Walked Per Day
Based on accelerometry data
Time frame: Up to week 12
Change From Baseline to Week 12 in Total Energy Expenditure
Metabolic equivalents of tasks \[METs\]. Based on accelerometry data
Time frame: Up to week 12
Change From Baseline to Week 12 in the Mean Duration of Moderate-to-vigorous Physical Activity
Defined as ≥3 METs. Based on accelerometry data
Time frame: Up to week 12
Change From Baseline to Week 12 in Pre- and Post-exercise Forced Expiratory Volume in One Second (FEV1)
Based on spirometry data
Time frame: Up to week 12
| Milestone | Placebo | Dupilumab |
|---|---|---|
| Started | 20 | 20 |
| Completed | 18 | 20 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Did not complete end of study follow-up | 1 | 0 |
CWRET (Constant Work Rate Exercise Test) will be performed on an electromagnetically-braked cycle ergometer in an exercise physiology laboratory overseen by a trained pulmonologist or medical doctor designee.
| Minutes | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test) | 0.923 (-0.614 to 2.460) | 1.742 (-0.054 to 3.538) |
Based on accelerometry data
| Steps | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline to Week 12 in Average Number of Steps Walked Per Day | -1066.11 (-2921.32 to 789.10) | 925.92 (-691.46 to 2543.30) |
Metabolic equivalents of tasks \[METs\]. Based on accelerometry data
| METs (metabolic equivalent of task) | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline to Week 12 in Total Energy Expenditure | 23.40 (-87.37 to 134.17) | 59.36 (-15.83 to 134.55) |
Defined as ≥3 METs. Based on accelerometry data
| Minutes | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline to Week 12 in the Mean Duration of Moderate-to-vigorous Physical Activity | -11.01 (-30.52 to 8.50) | 9.38 (-13.41 to 32.18) |
Based on spirometry data
| Liters | Placebo | Dupilumab |
|---|---|---|
| Change from Baseline to Week 12 (Pre-exercise) | 0.2123 (0.0072 to 0.4174) | 0.4205 (0.1409 to 0.7000) |
| Change from Baseline to Week 12 (2-min Post-Exercise) | 0.2550 (-0.2390 to 0.7490) | 0.2902 (0.0886 to 0.4919) |
| Change from Baseline to Week 12 (5-min Post-Exercise) | 0.2416 (0.0238 to 0.4593) | 0.4156 (0.1505 to 0.6808) |
| Change from Baseline to Week 12 (10-min Post-Exercise) | 0.2211 (0.0180 to 0.4243) | 0.4613 (0.2167 to 0.7060) |
| Change from Baseline to Week 12 (20-min Post-Exercise) | 0.2496 (0.0608 to 0.4384) | 0.4738 (0.2230 to 0.7245) |
Collected over Up to 22 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/20 (0%) | 0/20 (0%) | 9/20 (45%) |
| Dupilumab 300 mg Q2W | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Event | Placebo | Dupilumab 300 mg Q2W |
|---|---|---|
| COVID-19Infections and infestations | 3/20 | 0/20 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/20 | 1/20 |
| HeadacheNervous system disorders | 2/20 | 0/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/20 | 1/20 |
| Sinus painRespiratory, thoracic and mediastinal disorders | 0/20 | 1/20 |
| Injection site erythemaGeneral disorders | 0/20 | 1/20 |
| RhinitisInfections and infestations | 0/20 | 1/20 |
| BronchitisInfections and infestations | 1/20 | 0/20 |
| Respiratory tract infectionInfections and infestations | 1/20 | 0/20 |
| Immunisation reactionInjury, poisoning and procedural complications | 0/20 | 1/20 |
| Age, Continuous(Years) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Mean | 46.5 ± 7.7 | 45.3 ± 7.8 | 45.9 ± 7.7 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Female | 11 | 8 | 19 |
| Male | 9 | 12 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 19 | 18 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Dupilumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 18 | 19 | 37 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (eg, FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Jul 2020 to primary completion in Jul 2023, 35 months.
Results were first posted in Apr 2024, 9 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 35 months is above that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab